Morgan Stanley Maintains Thermo Fisher Scientific(TMO.US) With Buy Rating, Cuts Target Price to $670

摩根士丹利維持賽默飛世爾(TMO.US)買入評級，下調目標價至670美元

moomoo資訊 · 2024/10/25 18:34 · 評級/大行評級

Morgan Stanley analyst Tejas Savant maintains $Thermo Fisher Scientific (TMO.US)$ with a buy rating, and adjusts the target price from $680 to $670.

According to TipRanks data, the analyst has a success rate of 38.0% and a total average return of -6.5% over the past year.

AnalystRecentRatingAutoNews_202477_20241024_0aa31e5c31006a4af6d3663dbda4792a9d6f493b_1729859404609072_mm_en

Furthermore, according to the comprehensive report, the opinions of $Thermo Fisher Scientific (TMO.US)$'s main analysts recently are as follows:

The company delivered financial results that met expectations in a period where anticipation was high. It is recognized for maintaining strong performance amidst a challenging demand landscape for tools, with limited insight into when demand might rebound.
While the company's Q3 earnings call presented a more upbeat outlook than the actual results, there remains a positive sentiment towards the stock. Momentum in the Life Sciences Solutions segment is noted, particularly in bioproduction, and the Laboratory Products and Biopharma Services segment appears to be insulated from the biotech slowdown.
The firm notes that Thermo Fisher's core growth is showing a consistent improvement quarter-over-quarter, with guidance suggesting a slight increase to around +2.5% in the fourth quarter. The expectations of a 5% core growth by 2025 also appear to be reasonable and justifiable. The firm appreciates Thermo Fisher's resilient profile and the flexibility provided by its balance sheet.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

摩根士丹利分析師Tejas Savant維持$賽默飛世爾 (TMO.US)$買入評級，並將目標價從680美元下調至670美元。

根據TipRanks數據顯示，該分析師近一年總勝率為38.0%，總平均回報率為-6.5%。

AnalystRecentRatingAutoNews_202477_20241024_0aa31e5c31006a4af6d3663dbda4792a9d6f493b_1729859404609072_mm_tc

此外，綜合報道，$賽默飛世爾 (TMO.US)$近期主要分析師觀點如下：

在預期很高的時期，該公司公佈的財務業績符合預期。它因在充滿挑戰的工具需求格局中保持強勁的表現而受到認可，對需求何時可能反彈的了解有限。
儘管該公司的第三季度業績電話會議前景比實際業績更爲樂觀，但對該股的情緒仍然樂觀。生命科學解決方案板塊的勢頭顯而易見，尤其是在生物生產領域，實驗室產品和生物製藥服務板塊似乎不受生物技術放緩的影響。
該公司指出，賽默飛世爾的核心增長同比持續改善，指導表明第四季度略有增長至+2.5％左右。到2025年核心增長5％的預期似乎也是合理和合理的。該公司對賽默飛世爾的彈性表現及其資產負債表提供的靈活性表示讚賞。

提示:

TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。

TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。

分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。

總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

Morgan Stanley Maintains Thermo Fisher Scientific(TMO.US) With Buy Rating, Cuts Target Price to $670

Morgan Stanley Maintains Thermo Fisher Scientific(TMO.US) With Buy Rating, Cuts Target Price to $670

風險及免責聲明

聲明